Implementation of TMA and digitalization in routine diagnostics of breast pathology

APMIS

Volumn 120, Issue 4, 2012, Pages 341-347

  Rossing, Henrik Holm ^a   Talman, Maj Lis Møller ^a   Lænkholm, Anne Vibeke ^a,b   Wielenga, Vera Timmermans ^a  

^a Rigshospitalet   (Denmark)

^b SLAGELSE HOSPITAL   (Denmark)

Author keywords

Breast cancer; Digitalization; Fluorescense in situ hybridization; Immunohistochemistry; Routine diagnostics; TMA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR;

ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER SIZE; COST CONTROL; DIAGNOSTIC PROCEDURE; DIGITALIZATION; ECONOMIC ASPECT; FLUORESCENCE IN SITU HYBRIDIZATION; HEALTH CARE COST; HUMAN; HUMAN TISSUE; HYBRIDIZATION; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; STAINING; TISSUE MICROARRAY;

ANTIGENS, NEOPLASM; BREAST; BREAST NEOPLASMS; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IN SITU HYBRIDIZATION, FLUORESCENCE; MICROSCOPY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; STAINING AND LABELING; TISSUE ARRAY ANALYSIS;

EID: 84858670323     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2011.02871.x     Document Type: Article

References (19)

1. DBCG. Danish Breast cancer cooperative group. 2010.
2. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-83.
3. Early Breast cancer trialists′Collaborative group (EBCTCG). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011;378:771-84.
4. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER2/new oncogene. Science 1987;235:177-82.
5. Gianni L, Dafni U. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomized controlled trial. Lancet Oncol 2011;12:236-44.
6. Slamon D, Eiermann W, Robert N, Piekowski T. Breast Cancer international Research Group. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl J Med 2011;365:1273-83.
7. Ferretti G, Fabi A, Felici A, Papaldo P. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease. J Clin Oncol 2010;28:2525.
8. Hoang MP, Sahin AA, Ordòñez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. Am J Clin Pathol 2000;113:852-9.
9. Henriksen KL. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays. J Clin Pathol 2007;60:397-404.
10. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC. American society of clinical oncology/college of American pathologists guidelines recommendations for human epidermal growth factor receptor 2 in breast cancer. J’Clin Oncol 2007; 25: 118-45.
11. Winston JS, Ramanaryanan J, Levine E. HER-2/neu evaluation in breast cancer. Are we there yet? Am J Clin Pathol 2004;121(Suppl 1):S33-49.
12. Knoop AS, Knudsen H, Balslev E, Rasmussen BB, Overgaard J, Nielsen KV, et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005;23:7483-90.
13. Di Leo A, Desmedt C, Bartlett JM, Ejlertsen B, et al. Final results of a metaanalysis testing HER2 and topoisomerase II- genes as predictors of incremental benefit from anthracyclines in breast cancer. J Clin Oncol 2010; 102(Suppl 15): 519. (abstr 442324).
14. Kyndi M. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG82 b&c. Acta Oncol 2008;47:591-9.
15. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-7.
16. Viale V. Prognostic and predictive of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J’Clin Oncol 2007;25:3846-52.
17. Qureshi HS. E-Cadherin status in breastcancer correlates with histologic type but does not correlate with established prognostic parameters. Am J Clin Pathol 2006;125:377-85.
18. Da Silva L. Aberrant expression of E-cadherin in lobular carcinomas of the breast. Am J Surg Pathol 2008;32:773-83.
19. Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009;101:736-50.